Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model

MHAA4549A, a human monoclonal antibody targeting the hemagglutinin stalk region of influenza A virus (IAV), is being developed as a therapeutic for patients hospitalized with severe IAV infection. The safety and efficacy of MHAA4549A were assessed in a randomized, double-blind, placebo-controlled, d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: McBride, Jacqueline M., Lim, Jeremy J., Burgess, Tracy, Deng, Rong, Derby, Michael A., Maia, Mauricio, Horn, Priscilla, Siddiqui, Omer, Sheinson, Daniel, Chen-Harris, Haiyin, Newton, Elizabeth M., Fillos, Dimitri, Nazzal, Denise, Rosenberger, Carrie M., Ohlson, Maikke B., Lambkin-Williams, Rob, Fathi, Hosnieh, Harris, Jeffrey M., Tavel, Jorge A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2017
Schlagworte:
Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655070/
https://ncbi.nlm.nih.gov/pubmed/28807912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01154-17
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge